IDSA/SHEA Clostridium difficile Infection - Merck Flipbook

Clostridium Difficile - Treatment in Adults

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/943539

Contents of this Issue

Navigation

Page 2 of 9

Key Points • Clostridium difficile remains the most important cause of healthcare- associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. • Recent estimates suggest the U.S. burden of CDAD is close to 500,000 infections annually, although the exact magnitude of burden is highly dependent upon the type of diagnostic tests used. • Treatment recommendations no longer include metronidazole as first-line treatment of any severity. See Treatment section. Adult ➤ To increase comparability between clinical settings, use available standardized case definitions for surveillance of healthcare facility-onset (HO) CDAD; community-onset healthcare facility-associated (CO-HCFA); and community-associated (CA) CDAD (GP). ➤ At a minimum, conduct surveillance for HO-CDAD in all inpatient healthcare facilities to detect elevated rates or outbreaks within the facility (W-L). ➤ Express the rate of HO-CDAD as the number of cases per 10,000 patient- days. Express the CO-HCFA prevalence rate as the number of cases per 1,000 patient admissions (GP). ➤ Stratify data by patient location to target control measures when CDAD incidence is above national and/or facility reduction goals or if an outbreak is noted (W-L). Epidemiology

Articles in this issue

view archives of IDSA/SHEA Clostridium difficile Infection - Merck Flipbook - Clostridium Difficile - Treatment in Adults